Opioid Shareholders

A hyper-aggressive campaign by Insys Therapeutics directors to get doctors to push Subsys, a fentanyl sublingual spray, for off-label uses, caused the share price to plummet by 75 percent, shareholders say in a <strong><a href="http://www.courthousenews.com/wp-content/uploads/2018/08/Opioid.SD_.pdf">federal class action</a></strong>.

MANHATTAN — A hyper-aggressive campaign by Insys Therapeutics directors to get doctors to push Subsys, a fentanyl sublingual spray, for off-label uses, caused the share price to plummet by 75 percent, shareholders say in a federal class action .

Categories / Health, Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.